The official site for Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. Nasdaq: PGNX
New York, NY
Joined June 2009
- Tweets105
- Following94
- Followers277
- Likes77
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program globenewswire.com/NewsRoom/R…
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update bit.ly/3ce3atQ
Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7 bit.ly/2VPOqdU
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS bit.ly/2W6afYp
Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU) bit.ly/36Z6YM5
Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review bit.ly/38udJHa
Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting bit.ly/2FSyJeg
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint bit.ly/2QgopSh
Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd bit.ly/2sUNVUO
Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting bit.ly/2qA209I
Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer bit.ly/35lD04D
Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results bit.ly/2pTcxMy
Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations bit.ly/2ZOmZoU
Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update bit.ly/2YBNjTo
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) bit.ly/2T7nRPm
Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer bit.ly/2T5xsGB
Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 bit.ly/2YBu5bp
Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis bit.ly/2JSqbXM
Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial bit.ly/2JAJ3t0